Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections
Objectives Bendamustine is a standard treatment for low-grade B-cell lymphomas, and considered safe in clinical trials. Its safety in routine practice might be different.Methods We retrospectively analyzed the infection complications in an unselected cohort of patients treated with bendamustine over...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2072065 |
| _version_ | 1818007911346995200 |
|---|---|
| author | Tony K.Y. Wu Karen H.K. Tang Yu-Yan Hwang Thomas S.Y. Chan Eric Tse Yok-Lam Kwong |
| author_facet | Tony K.Y. Wu Karen H.K. Tang Yu-Yan Hwang Thomas S.Y. Chan Eric Tse Yok-Lam Kwong |
| author_sort | Tony K.Y. Wu |
| collection | DOAJ |
| description | Objectives Bendamustine is a standard treatment for low-grade B-cell lymphomas, and considered safe in clinical trials. Its safety in routine practice might be different.Methods We retrospectively analyzed the infection complications in an unselected cohort of patients treated with bendamustine over a nine-year period. Patients were regularly monitored for blood counts and cytomegalovirus (CMV) reactivation by antigen assay and polymerase chain reaction. They received granulocyte colony stimulating factor for neutropenia, and routine anti-pneumocystis and optional anti-fungal prophylaxis.Results There were 179 men and 127 women at a median age of 61.5 (20–90) years, 52% receiving bendamustine for relapsed/refractory disease. Malignancies included low-grade B-cell lymphomas (54%), myeloma (10%), T-cell lymphomas (11%), Hodgkin lymphoma (2%) and other lymphoid neoplasms (23%). Most patients had good performance status (Eastern Cooperative Oncology Group score: 0–1, 72%). CMV reactivation occurred in 58 patients (19%) at a median age of 68 (39–85) years. Univariate analysis showed CMV reactivation to be significantly associated with elevated lactate dehydrogenase (P = 0.045), decreased albumin (P = 0.003) and older age (reactivation versus no reactivation: 66.3 ± 11.4 versus 59.4 ± 14.5 years, P = 0.0016). Age remained the only significant risk on multivariate analysis. CMV reactivation resulted in retinitis (N = 4), ependymitis/ventriculitis (N = 1) and duodenitis/colitis (N = 1). Invasive fungal disease occurred in five patients (candidemia, N = 2; aspergillosis N = 1; cryptococcemia, N = 1; scedosporiosis, N–1). Nineteen patients had culture positive septicaemia.Conclusion Our observations showed that even with a vigorous anti-infective strategy, bendamustine treatment was still associated with significant risks of bacterial and opportunistic viral and fungal infections. |
| first_indexed | 2024-04-14T05:22:56Z |
| format | Article |
| id | doaj.art-e9e8908c358148bda5dc1d15fe8d661e |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-04-14T05:22:56Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-e9e8908c358148bda5dc1d15fe8d661e2022-12-22T02:10:08ZengTaylor & Francis GroupHematology1607-84542022-12-0127153554210.1080/16078454.2022.2072065Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infectionsTony K.Y. Wu0Karen H.K. Tang1Yu-Yan Hwang2Thomas S.Y. Chan3Eric Tse4Yok-Lam Kwong5Department of Medicine, Queen Mary Hospital, Pokfulam, Hong KongDepartment of Medicine, Queen Mary Hospital, Pokfulam, Hong KongDepartment of Medicine, Queen Mary Hospital, Pokfulam, Hong KongDepartment of Medicine, Queen Mary Hospital, Pokfulam, Hong KongDepartment of Medicine, Queen Mary Hospital, Pokfulam, Hong KongDepartment of Medicine, Queen Mary Hospital, Pokfulam, Hong KongObjectives Bendamustine is a standard treatment for low-grade B-cell lymphomas, and considered safe in clinical trials. Its safety in routine practice might be different.Methods We retrospectively analyzed the infection complications in an unselected cohort of patients treated with bendamustine over a nine-year period. Patients were regularly monitored for blood counts and cytomegalovirus (CMV) reactivation by antigen assay and polymerase chain reaction. They received granulocyte colony stimulating factor for neutropenia, and routine anti-pneumocystis and optional anti-fungal prophylaxis.Results There were 179 men and 127 women at a median age of 61.5 (20–90) years, 52% receiving bendamustine for relapsed/refractory disease. Malignancies included low-grade B-cell lymphomas (54%), myeloma (10%), T-cell lymphomas (11%), Hodgkin lymphoma (2%) and other lymphoid neoplasms (23%). Most patients had good performance status (Eastern Cooperative Oncology Group score: 0–1, 72%). CMV reactivation occurred in 58 patients (19%) at a median age of 68 (39–85) years. Univariate analysis showed CMV reactivation to be significantly associated with elevated lactate dehydrogenase (P = 0.045), decreased albumin (P = 0.003) and older age (reactivation versus no reactivation: 66.3 ± 11.4 versus 59.4 ± 14.5 years, P = 0.0016). Age remained the only significant risk on multivariate analysis. CMV reactivation resulted in retinitis (N = 4), ependymitis/ventriculitis (N = 1) and duodenitis/colitis (N = 1). Invasive fungal disease occurred in five patients (candidemia, N = 2; aspergillosis N = 1; cryptococcemia, N = 1; scedosporiosis, N–1). Nineteen patients had culture positive septicaemia.Conclusion Our observations showed that even with a vigorous anti-infective strategy, bendamustine treatment was still associated with significant risks of bacterial and opportunistic viral and fungal infections.https://www.tandfonline.com/doi/10.1080/16078454.2022.2072065Bendamustinecytomegalovirusinvasive fungal diseaseopportunistic infections |
| spellingShingle | Tony K.Y. Wu Karen H.K. Tang Yu-Yan Hwang Thomas S.Y. Chan Eric Tse Yok-Lam Kwong Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections Hematology Bendamustine cytomegalovirus invasive fungal disease opportunistic infections |
| title | Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections |
| title_full | Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections |
| title_fullStr | Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections |
| title_full_unstemmed | Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections |
| title_short | Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections |
| title_sort | bendamustine treatment of haematological malignancies significant risks of opportunistic viral fungal and bacterial infections |
| topic | Bendamustine cytomegalovirus invasive fungal disease opportunistic infections |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2022.2072065 |
| work_keys_str_mv | AT tonykywu bendamustinetreatmentofhaematologicalmalignanciessignificantrisksofopportunisticviralfungalandbacterialinfections AT karenhktang bendamustinetreatmentofhaematologicalmalignanciessignificantrisksofopportunisticviralfungalandbacterialinfections AT yuyanhwang bendamustinetreatmentofhaematologicalmalignanciessignificantrisksofopportunisticviralfungalandbacterialinfections AT thomassychan bendamustinetreatmentofhaematologicalmalignanciessignificantrisksofopportunisticviralfungalandbacterialinfections AT erictse bendamustinetreatmentofhaematologicalmalignanciessignificantrisksofopportunisticviralfungalandbacterialinfections AT yoklamkwong bendamustinetreatmentofhaematologicalmalignanciessignificantrisksofopportunisticviralfungalandbacterialinfections |